Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avitar set to expand with $10million funding:

This article was originally published in Clinica

Executive Summary

Oral fluid diagnostics specialist Avitar has signed a $10m standby equity financing deal with Cornell Capital Partners. Avitar's chairman and CEO, Peter Phildius, explained that the financing would provide the working capital to invest in resources to "enhance and expand" its ORALscreen business. ORALscreen is a noninvasive, rapid, onsite oral fluid test for drugs of abuse, targeting a $1.5bn market. Avitar will be able to draw $250,000 tranches at any time, up to a maximum of $1m a month. Avitar is based in Canton, Massachusetts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts